Canton Biologics (Hanten Biotech)
广州汉腾生物科技有限公司
South China's largest large-molecule biologics CDMO — antibody/recombinant-protein focused, with strong process development and downstream and ~13,000 L GMP capacity across two GBA bases. A credible recombinant-protein and (smaller) microbial-fermentation partner, with the caveat that the core is mammalian CHO antibody work.
- Location
- Guangzhou (HQ); Foshan Kunlun & Guangzhou Penglai GMP bases · Guangzhou
- Visit window
- Day-trip from Shenzhen · Weeks 2–4
- Source status
- medium confidencecandidate
Next action
Keep the dossier ready and use the open questions if a visit window opens.
Why now: Visit window · Day-trip from Shenzhen · Weeks 2–4
What they do
Founded 2016 in Guangzhou; national high-tech enterprise; an international large-molecule biopharma CDMO. End-to-end DNA-to-IND-to-commercial services: cell-line development, upstream and downstream process development, formulation, fill-finish, characterisation, validation and GMP production.
Modalities span mAbs, bispecifics, fusion and recombinant proteins, recombinant vaccines, viral vectors and cell therapy, and it lists a dedicated microbial platform among services. Claims 100+ clients, 400+ delivered projects and 50+ external audits passed.
Why it matters
Medium fit on the biomanufacturing leg of Pure Advance's platform: a high-end GBA biologics CDMO with mature process development, downstream purification and GMP discipline that also lists recombinant-protein and microbial service lines. Value is learning whether that microbial line can take an external pilot-scale fermentation project; the core business is mammalian-cell antibody work, and topical relevance is indirect.
Visit objective & route
Meet to learn whether the microbial / recombinant-protein line can take an external pilot-scale fermentation project (biocontrol protein or enzyme), benchmark a high-end CDMO's process-dev/QA, and confirm which site to visit.
Approach route
Appointment-only via BD/contact page; GBA day-trip (Foshan / Guangzhou).
Talking points
- Does the microbial / recombinant-protein service line accept external pilot-scale fermentation projects (5 L to 1000 L+), e.g. a biocontrol protein or enzyme?
- What is the capacity split (mammalian vs microbial), and lead times / MOQ for a small pilot?
- Do you have export/quality documentation and KSA/GCC suitability for a protein-based active?
- Confirm which site to visit (HQ meeting vs GMP plant tour).
Open questions
- Whether the microbial line is a genuine external service or a minor adjunct to the mammalian CHO core.
- Capacity split (mammalian vs microbial), lead times and MOQ for a small pilot.
- Export/quality docs and KSA/GCC suitability for a protein-based active.
- Confirm a direct BD/commercial contact and which site to visit before travel.
Risks & unknowns
- Core business is mammalian-cell (CHO) antibody CDMO, not microbial fermentation — fit for the microbial pilot priority is unproven.
- Topical relevance is indirect (protein/peptide active supply at most).
- Appointment-only; direct BD contact not captured.
Private-pack boundary